NASDAQ:GTHX G1 Therapeutics (GTHX) Stock Price, News & Analysis → 8,788% Return Predicted For THIS Crypto (already up 40% in 6 months) (From Paradigm Press) (Ad) Free GTHX Stock Alerts $3.21 +0.10 (+3.22%) (As of 03/18/2024 ET) Add Compare Share Share Today's Range$2.93▼$3.4050-Day Range$2.10▼$4.8352-Week Range$1.08▼$5.00Volume815,317 shsAverage Volume1.16 million shsMarket Capitalization$167.56 millionP/E RatioN/ADividend YieldN/APrice Target$9.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get G1 Therapeutics alerts: Email Address G1 Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside190.8% Upside$9.33 Price TargetShort InterestHealthy5.57% of Shares Sold ShortDividend StrengthN/ASustainability-2.45Upright™ Environmental ScoreNews Sentiment0.52Based on 4 Articles This WeekInsider TradingSelling Shares$251,852 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.64) to ($0.26) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.97 out of 5 starsMedical Sector220th out of 946 stocksPharmaceutical Preparations Industry97th out of 433 stocks 3.3 Analyst's Opinion Consensus RatingG1 Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.33, G1 Therapeutics has a forecasted upside of 190.8% from its current price of $3.21.Amount of Analyst CoverageG1 Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted5.57% of the outstanding shares of G1 Therapeutics have been sold short.Short Interest Ratio / Days to CoverG1 Therapeutics has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in G1 Therapeutics has recently decreased by 12.61%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldG1 Therapeutics does not currently pay a dividend.Dividend GrowthG1 Therapeutics does not have a long track record of dividend growth. Previous Next 3.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreG1 Therapeutics has received a 49.69% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Detoxifying agents for antineoplastic treatment (V03AF)" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for G1 Therapeutics is -2.45. Previous Next 2.5 News and Social Media Coverage News SentimentG1 Therapeutics has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for G1 Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 11 people have searched for GTHX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows6 people have added G1 Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, G1 Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $251,852.00 in company stock.Percentage Held by InsidersOnly 8.23% of the stock of G1 Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 30.04% of the stock of G1 Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for G1 Therapeutics are expected to grow in the coming year, from ($0.64) to ($0.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of G1 Therapeutics is -3.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of G1 Therapeutics is -3.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioG1 Therapeutics has a P/B Ratio of 4.72. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaLike Tiny Crypto Retirement FundsThe crypto bull market is about to blast off. Bitcoin and Ethereum are surging. But so are tiny altcoins that could be so profitable… They're like tiny crypto retirement funds. Click here and see how to get a copy. About G1 Therapeutics Stock (NASDAQ:GTHX)G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor can protect bone marrow and reduce hematologic adverse events (AEs), as well as improve emerging treatments through myeloprotection which improve patients' overall anti-tumor immune responses combination with the antibody-drug conjugate; and treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.Read More GTHX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GTHX Stock News HeadlinesMarch 16, 2024 | finance.yahoo.comGTHX Apr 2024 3.000 callMarch 16, 2024 | finance.yahoo.comGTHX Apr 2024 3.500 putMarch 19, 2024 | Behind the Markets (Ad)The only AI company you should be looking atThis is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.March 6, 2024 | finance.yahoo.comGTHX Mar 2024 3.000 putMarch 1, 2024 | globenewswire.comG1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 1, 2024 | seekingalpha.comG1 Therapeutics, Inc. (GTHX) Q4 2023 Earnings Call TranscriptFebruary 29, 2024 | markets.businessinsider.comBuy Rating Justified by G1 Therapeutics’ Strong Q4 Earnings and Cosela’s Market TractionFebruary 29, 2024 | finance.yahoo.comG1 Therapeutics, Inc. (NASDAQ:GTHX) Q4 2023 Earnings Call TranscriptMarch 19, 2024 | Behind the Markets (Ad)The only AI company you should be looking atThis is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.February 29, 2024 | finance.yahoo.comQ4 2023 G1 Therapeutics Inc Earnings CallFebruary 28, 2024 | investing.comG1 Therapeutics Inc (GTHX)February 28, 2024 | finance.yahoo.comGTHX Jul 2024 2.500 putFebruary 28, 2024 | msn.comG1 Therapeutics GAAP EPS of -$0.21 beats by $0.07, revenue of $14.9M beats by $1.87MFebruary 28, 2024 | markets.businessinsider.comForecasting The Future: 5 Analyst Projections For G1 TherapeuticsFebruary 28, 2024 | finance.yahoo.comG1 Therapeutics Inc (GTHX) Reports Strong Revenue Growth in 2023February 28, 2024 | globenewswire.comG1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational HighlightsFebruary 27, 2024 | globenewswire.comG1 Therapeutics to Participate in the TD Cowen 44th Annual Health Care ConferenceFebruary 17, 2024 | finance.yahoo.comG1 Therapeutics, Inc.'s (NASDAQ:GTHX) 47% loss last week hit both individual investors who own 60% as well as institutionsFebruary 15, 2024 | finance.yahoo.comG1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024February 15, 2024 | globenewswire.comG1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024February 14, 2024 | finance.yahoo.comGTHX Feb 2024 7.500 putFebruary 13, 2024 | msn.comG1 Therapeutics stock sinks 53% in wake of study updateFebruary 13, 2024 | marketwatch.comG1 Therapeutics Shares Down 54% After Cancer Study Update, Wedbush Price Target CutFebruary 13, 2024 | msn.comG1 Therapeutics, CareCloud among healthcare moversFebruary 13, 2024 | investorplace.comWhy Is G1 Therapeutics (GTHX) Stock Down 45% Today?February 12, 2024 | marketwatch.comShares G1 Therapeutics Tumble 46% Following Update to Phase 3 Breast Cancer StudyFebruary 12, 2024 | finance.yahoo.comG1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring CommitteeSee More Headlines Receive GTHX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for G1 Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today3/18/2024Next Earnings (Estimated)5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GTHX CUSIPN/A CIK1560241 Webwww.g1therapeutics.com Phone(919) 213-9835Fax919-741-5830Employees100Year FoundedN/APrice Target and Rating Average Stock Price Target$9.33 High Stock Price Target$12.00 Low Stock Price Target$5.00 Potential Upside/Downside+190.8%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-47,970,000.00 Net Margins-58.13% Pretax Margin-54.36% Return on Equity-106.04% Return on Assets-33.99% Debt Debt-to-Equity Ratio1.46 Current Ratio3.87 Quick Ratio3.45 Sales & Book Value Annual Sales$82.51 million Price / Sales2.03 Cash FlowN/A Price / Cash FlowN/A Book Value$0.68 per share Price / Book4.72Miscellaneous Outstanding Shares52,200,000Free Float47,903,000Market Cap$167.56 million OptionableOptionable Beta1.70 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. John E. Bailey Jr. (Age 59)CEO, President & Director Comp: $1.06MMr. Mark Avagliano (Age 48)Chief Business Officer Comp: $628.54kMr. John W. Umstead V (Age 39)Chief Financial Officer Mr. Terry L. Murdock (Age 64)Chief Operating Officer Comp: $541.59kMr. William C. Roberts (Age 55)Vice President of Investor Relations & Corporate Communications Ms. Monica R. ThomasGeneral Counsel & Chief Compliance OfficerMr. Evan Hicks M.B.A.Vice President of MarketingDr. Rajesh K. Malik Ch.B. (Age 65)M.B., M.D., Chief Medical Officer Comp: $596.37kMr. Andrew Perry (Age 51)Chief Commercial Officer Comp: $568.6kMr. Jeff MacdonaldSenior Director of Investor Relations & Corporate CommunicationsMore ExecutivesKey CompetitorsImmuneeringNASDAQ:IMRXSpyre TherapeuticsNASDAQ:SYRENuvectis PharmaNASDAQ:NVCTAldeyra TherapeuticsNASDAQ:ALDXGlycoMimeticsNASDAQ:GLYCView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 31,605 shares on 3/11/2024Ownership: 3.796%Goldman Sachs Group Inc.Sold 4,829 shares on 3/1/2024Ownership: 0.022%Virtu Financial LLCBought 44,726 shares on 2/26/2024Ownership: 0.086%GSA Capital Partners LLPBought 6,651 shares on 2/16/2024Ownership: 0.050%Bridgeway Capital Management LLCSold 20,000 shares on 2/15/2024Ownership: 0.231%View All Insider TransactionsView All Institutional Transactions GTHX Stock Analysis - Frequently Asked Questions Should I buy or sell G1 Therapeutics stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last twelve months. There are currently 1 sell rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" GTHX shares. View GTHX analyst ratings or view top-rated stocks. What is G1 Therapeutics' stock price target for 2024? 4 brokers have issued 12-month price objectives for G1 Therapeutics' shares. Their GTHX share price targets range from $5.00 to $12.00. On average, they anticipate the company's share price to reach $9.33 in the next year. This suggests a possible upside of 190.8% from the stock's current price. View analysts price targets for GTHX or view top-rated stocks among Wall Street analysts. How have GTHX shares performed in 2024? G1 Therapeutics' stock was trading at $3.05 at the beginning of the year. Since then, GTHX shares have increased by 5.2% and is now trading at $3.21. View the best growth stocks for 2024 here. Are investors shorting G1 Therapeutics? G1 Therapeutics saw a decline in short interest in February. As of February 29th, there was short interest totaling 2,910,000 shares, a decline of 12.6% from the February 14th total of 3,330,000 shares. Based on an average daily trading volume, of 1,930,000 shares, the short-interest ratio is currently 1.5 days. View G1 Therapeutics' Short Interest. When is G1 Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our GTHX earnings forecast. How were G1 Therapeutics' earnings last quarter? G1 Therapeutics, Inc. (NASDAQ:GTHX) issued its quarterly earnings data on Wednesday, February, 28th. The company reported ($0.21) earnings per share for the quarter, beating analysts' consensus estimates of ($0.27) by $0.06. The company earned $14.87 million during the quarter, compared to analyst estimates of $12.83 million. G1 Therapeutics had a negative net margin of 58.13% and a negative trailing twelve-month return on equity of 106.04%. During the same quarter last year, the company posted ($0.73) earnings per share. What other stocks do shareholders of G1 Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other G1 Therapeutics investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Kadmon (KDMN), VBI Vaccines (VBIV), Novavax (NVAX) and Pfizer (PFE). When did G1 Therapeutics IPO? (GTHX) raised $101 million in an initial public offering (IPO) on Wednesday, May 17th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers. Who are G1 Therapeutics' major shareholders? G1 Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.82%), Vanguard Group Inc. (3.80%), Raymond James & Associates (1.09%), abrdn plc (0.82%), Needham Investment Management LLC (0.35%) and Level Four Advisory Services LLC (0.34%). Insiders that own company stock include Andrew Perry, James S Hanson, Jennifer K Moses, John E (Jack) Jr Bailey, John W V Umstead, Mark A Velleca, Mark A Velleca, Rajesh Malik, Seth Rudnick and Terry L Murdock. View institutional ownership trends. How do I buy shares of G1 Therapeutics? Shares of GTHX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GTHX) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceStock-Picking AI Predicts #1 Stock of 2024AltimetrySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding G1 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.